A private, U.S.-based e-commerce platform launched in October 2025 specializes in selling research-use-only peptides. Within nine months, the platform reached an annual run-rate of approximately $22 million, averaging around $1.85 million per month. The platform is bootstrapped and profitable without any external capital. The business is listed privately due to its regulatory-sensitive category, and the owner seeks confidentiality during the sale process. The owner, the main architect of the brand and its growth, intends to sell the business as part of a planned transition. They are open to various sale structures, including a full sale, rollover equity, earnouts, and post-sale consulting, while ensuring a structured handover and knowledge transfer. Operating as a single-brand e-commerce business, it doesn't rely on wholesale or marketplaces like Amazon. It generates revenue through five product categories: metabolic health, growth-hormone secretagogues, recovery and healing, longevity and cellular health, and specialty accessories. The pricing strategy is tiered by dosage, with bundle and protocol pricing options. The company operates with a lean, asset-light model, outsourcing manufacturing to third-party logistics and maintaining a small customer service team. The technology stack includes third-party platforms for storefronts, payments, and fulfillment, reducing high-risk processing concentration effectively. Since its inception, the platform has demonstrated strong financial growth, achieving profitability quickly, and reaching significant monthly revenue figures. The platform's payment-processing fees account for about 7% of sales due to its high-risk category classification. Financial details and further inquiries are available through direct communication on the listing platform, pending buyer verification.